- Home
- IDYA vs FINV Comparison
IDYA vs FINV Comparison
Compare IDYA & FINV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDYA
- FINV
- Stock Information
- Founded
- IDYA 2015
- FINV 2007
- Country
- IDYA United States
- FINV China
- Employees
- IDYA N/A
- FINV N/A
- Industry
- IDYA Biotechnology: Pharmaceutical Preparations
- FINV Finance: Consumer Services
- Sector
- IDYA Health Care
- FINV Finance
- Exchange
- IDYA Nasdaq
- FINV Nasdaq
- Market Cap
- IDYA 1.9B
- FINV 2.2B
- IPO Year
- IDYA 2019
- FINV N/A
- Fundamental
- Price
- IDYA $21.23
- FINV $9.45
- Analyst Decision
- IDYA Strong Buy
- FINV Strong Buy
- Analyst Count
- IDYA 13
- FINV 2
- Target Price
- IDYA $53.42
- FINV $11.55
- AVG Volume (30 Days)
- IDYA 1.1M
- FINV 1.7M
- Earning Date
- IDYA 08-05-2025
- FINV 08-19-2025
- Dividend Yield
- IDYA N/A
- FINV 2.97%
- EPS Growth
- IDYA N/A
- FINV 26.19
- EPS
- IDYA N/A
- FINV 1.37
- Revenue
- IDYA $7,000,000.00
- FINV $1,846,779,164.00
- Revenue This Year
- IDYA $101.20
- FINV $13.72
- Revenue Next Year
- IDYA $286.70
- FINV $11.25
- P/E Ratio
- IDYA N/A
- FINV $6.95
- Revenue Growth
- IDYA N/A
- FINV 5.40
- 52 Week Low
- IDYA $13.45
- FINV $4.77
- 52 Week High
- IDYA $44.42
- FINV $11.08
- Technical
- Relative Strength Index (RSI)
- IDYA 62.23
- FINV 61.38
- Support Level
- IDYA $21.08
- FINV $9.10
- Resistance Level
- IDYA $22.37
- FINV $9.75
- Average True Range (ATR)
- IDYA 0.92
- FINV 0.30
- MACD
- IDYA -0.09
- FINV 0.08
- Stochastic Oscillator
- IDYA 61.72
- FINV 69.18
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
About FINV FinVolution Group
FinVolution Group is a provider of online consumer finance in China. The company offers various loan products, making financial services available to borrowers anytime, anywhere; designs a loan transaction process, and offers tailored risk-based pricing. It offers short-term loans to borrowers to meet immediate credit needs while allowing them to gradually establish their credit history through activities on the company's platform. The company generates revenues from fees charged to borrowers. The Group's long-lived assets are located in the PRC, and its revenues are derived from within the PRC.